RAP 0.00% 20.5¢ raptor resources limited

2 glaring issues for DX that I believe RAP needs to fix:1) Tony...

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 644 Posts.
    lightbulb Created with Sketch. 81
    2 glaring issues for DX that I believe RAP needs to fix:

    1) Tony is still talking about DX as an "ADD-ON":
    DX is only available to Telehealth providers (Coviu and Phenix) as a 3rd party add-on is very disappointing.
    Doctors are not going to download add-ons. I wouldn't want my GP using a 3rd party app to diagnose me either- I personally would not trust it.
    DX needs to be integrated into the platforms and backed by the providers to offer training / education on its use.

    2) Branding:
    The current implementation does not instill confidence for consumers or doctors - If DX was branded as a clinically validated "virtual stethoscope" and integrated into an established platform (Healthdirect or Coviu) I think it would have far better uptake.

    "Virtual stethoscope" works as both consumers and doctors will immediately understand what it's for and what gap it fills in a teleheath setting.
    The Stethoscope has been a trusted clinical tool for almost 200 years and is still used in most respiratory consultations. Who would trust a doctor to diagnose their respiratory condition without using one.

    Feel free to email these suggestions to Tony
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.